Sartorius Stedim Biotech Q1 Profit Up 3%

Sartorius Stedim Biotech reported Q1 net profit €88 million, up 3% YoY, with sales €761.5 million, up 2.3% (7.9% constant‑currency).
Underlying EBITDA reached €233.4 million, a 1.9% rise, margin 30.7% versus 30.8% last year; EPS €1.17 underlying, €0.91 reported.
Operating cash flow surged 61.4% to €193.3 million; free cash flow more than doubled to €123.7 million; capex €69.6 million (9.1% of sales).
Management reaffirmed FY2026 guidance: constant‑currency sales growth 6‑10%, EBITDA margin slightly above 31%, net‑debt/EBITDA just above 2.